National Research Corporation Logo

National Research Corporation

NRC

(2.5)
Stock Price

19,14 USD

52.19% ROA

63.64% ROE

15.9x PER

Market Cap.

465.251.637,00 USD

105.03% DER

2.46% Yield

20.01% NPM

National Research Corporation Stock Analysis

National Research Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

National Research Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (39.94%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (26%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

5 Dividend Growth

Investors can take confidence in the company's impressive track record of annual dividend growth over the last three years, showcasing a commitment to providing higher returns.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (207), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (13.04x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

National Research Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

National Research Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

National Research Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

National Research Corporation Revenue
Year Revenue Growth
1993 2.811.000
1994 6.755.000 58.39%
1995 8.917.000 24.25%
1996 12.600.000 29.23%
1997 16.300.000 22.7%
1998 17.700.000 7.91%
1999 18.200.000 2.75%
2000 18.316.116 0.63%
2001 17.673.988 -3.63%
2002 22.387.401 21.05%
2003 26.922.000 16.84%
2004 29.683.091 9.3%
2005 32.436.000 8.49%
2006 43.771.455 25.9%
2007 48.922.884 10.53%
2008 51.013.000 4.1%
2009 57.692.000 11.58%
2010 63.398.000 9%
2011 75.767.000 16.33%
2012 86.421.000 12.33%
2013 92.590.000 6.66%
2014 98.837.000 6.32%
2015 102.343.000 3.43%
2016 109.384.000 6.44%
2017 117.559.000 6.95%
2018 119.686.000 1.78%
2019 127.982.000 6.48%
2020 133.277.000 3.97%
2021 147.954.000 9.92%
2022 151.568.000 2.38%
2023 151.780.000 0.14%
2023 148.580.000 -2.15%
2024 140.084.000 -6.06%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

National Research Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

National Research Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 4.000.000 100%
1998 4.800.000 16.67%
1999 4.200.000 -14.29%
2000 4.602.223 8.74%
2001 4.985.328 7.68%
2002 4.737.880 -5.22%
2003 5.987.000 20.86%
2004 7.394.567 19.04%
2005 8.617.000 14.19%
2006 12.158.004 29.12%
2007 13.173.431 7.71%
2008 12.728.081 -3.5%
2009 15.590.000 18.36%
2010 20.202.000 22.83%
2011 23.300.000 13.3%
2012 23.542.000 1.03%
2013 25.208.000 6.61%
2014 25.018.000 -0.76%
2015 27.177.000 7.94%
2016 28.385.000 4.26%
2017 29.686.000 4.38%
2018 31.371.000 5.37%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

National Research Corporation EBITDA
Year EBITDA Growth
1993 561.000
1994 1.744.000 67.83%
1995 3.058.000 42.97%
1996 3.600.000 15.06%
1997 6.400.000 43.75%
1998 5.700.000 -12.28%
1999 3.300.000 -72.73%
2000 4.632.566 28.77%
2001 4.649.614 0.37%
2002 8.159.304 43.01%
2003 8.820.000 7.49%
2004 9.424.042 6.41%
2005 10.186.000 7.48%
2006 12.223.419 16.67%
2007 13.852.145 11.76%
2008 14.716.000 5.87%
2009 17.530.000 16.05%
2010 18.567.000 5.59%
2011 23.813.000 22.03%
2012 27.447.000 13.24%
2013 28.617.000 4.09%
2014 32.201.000 11.13%
2015 31.689.000 -1.62%
2016 35.771.000 11.41%
2017 38.951.000 8.16%
2018 41.685.000 6.56%
2019 48.149.000 13.42%
2020 50.252.000 4.18%
2021 56.662.000 11.31%
2022 51.870.000 -9.24%
2023 47.016.000 -10.32%
2023 45.985.000 -2.24%
2024 41.512.000 -10.78%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

National Research Corporation Gross Profit
Year Gross Profit Growth
1993 1.728.000
1994 3.788.000 54.38%
1995 5.422.000 30.14%
1996 6.900.000 21.42%
1997 9.100.000 24.18%
1998 8.300.000 -9.64%
1999 7.100.000 -16.9%
2000 9.196.366 22.8%
2001 9.614.591 4.35%
2002 12.831.724 25.07%
2003 14.893.000 13.84%
2004 16.813.832 11.42%
2005 18.794.000 10.54%
2006 24.325.530 22.74%
2007 27.121.845 10.31%
2008 27.402.000 1.02%
2009 33.118.000 17.26%
2010 38.763.000 14.56%
2011 47.100.000 17.7%
2012 50.960.000 7.57%
2013 53.746.000 5.18%
2014 57.118.000 5.9%
2015 57.733.000 1.07%
2016 63.807.000 9.52%
2017 68.491.000 6.84%
2018 72.109.000 5.02%
2019 81.547.000 11.57%
2020 84.090.000 3.02%
2021 95.604.000 12.04%
2022 94.519.000 -1.15%
2023 93.248.000 -1.36%
2023 86.666.000 -7.59%
2024 80.344.000 -7.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

National Research Corporation Net Profit
Year Net Profit Growth
1993 514.000
1994 1.590.000 67.67%
1995 3.047.000 47.82%
1996 2.300.000 -32.48%
1997 3.200.000 28.13%
1998 500.000 -540%
1999 1.500.000 66.67%
2000 2.716.727 44.79%
2001 1.670.321 -62.65%
2002 3.850.103 56.62%
2003 4.384.000 12.18%
2004 4.550.634 3.66%
2005 5.236.000 13.09%
2006 5.884.068 11.01%
2007 6.839.012 13.96%
2008 7.445.000 8.14%
2009 8.491.000 12.32%
2010 8.499.000 0.09%
2011 11.564.000 26.5%
2012 15.068.000 23.25%
2013 15.484.000 2.69%
2014 18.156.000 14.72%
2015 17.610.000 -3.1%
2016 20.518.000 14.17%
2017 22.943.000 10.57%
2018 30.047.000 23.64%
2019 32.406.000 7.28%
2020 37.260.000 13.03%
2021 37.466.000 0.55%
2022 31.800.000 -17.82%
2023 31.504.000 -0.94%
2023 30.971.000 -1.72%
2024 24.700.000 -25.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

National Research Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 1 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1 0%
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 100%
2008 1 0%
2009 1 0%
2010 1 0%
2011 2 0%
2012 2 50%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 1 0%
2018 1 100%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

National Research Corporation Free Cashflow
Year Free Cashflow Growth
1996 6.000.000
1997 1.200.000 -400%
1998 -3.800.000 131.58%
1999 -1.400.000 -171.43%
2000 -4.171.006 66.43%
2001 1.536.366 371.49%
2002 2.750.003 44.13%
2003 6.582.000 58.22%
2004 5.749.922 -14.47%
2005 7.100.000 19.02%
2006 5.359.052 -32.49%
2007 12.609.910 57.5%
2008 12.363.031 -2%
2009 10.757.000 -14.93%
2010 13.064.000 17.66%
2011 15.669.000 16.63%
2012 16.784.000 6.64%
2013 17.127.000 2%
2014 23.705.000 27.75%
2015 18.947.000 -25.11%
2016 22.870.000 17.15%
2017 23.273.000 1.73%
2018 33.877.000 31.3%
2019 36.261.000 6.57%
2020 36.652.000 1.07%
2021 40.830.000 10.23%
2022 26.430.000 -54.48%
2023 22.334.000 -18.34%
2023 5.347.000 -317.69%
2024 1.517.000 -252.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

National Research Corporation Operating Cashflow
Year Operating Cashflow Growth
1996 6.300.000
1997 1.500.000 -320%
1998 4.000.000 62.5%
1999 3.500.000 -14.29%
2000 2.023.312 -72.98%
2001 3.079.652 34.3%
2002 4.284.083 28.11%
2003 8.265.000 48.17%
2004 7.816.729 -5.73%
2005 8.188.000 4.53%
2006 6.812.180 -20.2%
2007 14.566.114 53.23%
2008 15.175.381 4.01%
2009 13.666.000 -11.04%
2010 14.603.000 6.42%
2011 18.481.000 20.98%
2012 19.132.000 3.4%
2013 19.315.000 0.95%
2014 26.197.000 26.27%
2015 21.886.000 -19.7%
2016 26.843.000 18.47%
2017 28.091.000 4.44%
2018 39.848.000 29.5%
2019 40.917.000 2.61%
2020 40.636.000 -0.69%
2021 46.344.000 12.32%
2022 36.265.000 -27.79%
2023 38.113.000 4.85%
2023 9.817.000 -288.23%
2024 6.787.000 -44.64%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

National Research Corporation Capital Expenditure
Year Capital Expenditure Growth
1996 300.000
1997 300.000 0%
1998 7.800.000 96.15%
1999 4.900.000 -59.18%
2000 6.194.318 20.9%
2001 1.543.286 -301.37%
2002 1.534.080 -0.6%
2003 1.683.000 8.85%
2004 2.066.807 18.57%
2005 1.088.000 -89.96%
2006 1.453.128 25.13%
2007 1.956.204 25.72%
2008 2.812.350 30.44%
2009 2.909.000 3.32%
2010 1.539.000 -89.02%
2011 2.812.000 45.27%
2012 2.348.000 -19.76%
2013 2.188.000 -7.31%
2014 2.492.000 12.2%
2015 2.939.000 15.21%
2016 3.973.000 26.03%
2017 4.818.000 17.54%
2018 5.971.000 19.31%
2019 4.656.000 -28.24%
2020 3.984.000 -16.87%
2021 5.514.000 27.75%
2022 9.835.000 43.93%
2023 15.779.000 37.67%
2023 4.470.000 -253%
2024 5.270.000 15.18%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

National Research Corporation Equity
Year Equity Growth
1993 290.000
1994 1.623.000 82.13%
1995 1.830.000 11.31%
1996 2.100.000 12.86%
1997 18.100.000 88.4%
1998 17.400.000 -4.02%
1999 18.600.000 6.45%
2000 21.382.431 13.01%
2001 23.353.398 8.44%
2002 28.018.275 16.65%
2003 32.424.000 13.59%
2004 35.017.657 7.41%
2005 32.593.000 -7.44%
2006 36.750.513 11.31%
2007 42.286.433 13.09%
2008 38.598.000 -9.56%
2009 44.171.000 12.62%
2010 48.584.000 9.08%
2011 55.554.000 12.55%
2012 56.742.000 2.09%
2013 71.755.000 20.92%
2014 87.748.000 18.23%
2015 74.222.000 -18.22%
2016 82.806.000 10.37%
2017 90.041.000 8.04%
2018 19.083.000 -371.84%
2019 32.892.000 41.98%
2020 64.315.000 48.86%
2021 85.337.000 24.63%
2022 72.033.000 -18.47%
2023 48.955.000 -47.14%
2023 57.872.000 15.41%
2024 40.198.000 -43.97%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

National Research Corporation Assets
Year Assets Growth
1993 1.368.000
1994 3.539.000 61.35%
1995 4.996.000 29.16%
1996 6.200.000 19.42%
1997 22.600.000 72.57%
1998 26.300.000 14.07%
1999 29.300.000 10.24%
2000 31.637.473 7.39%
2001 33.772.392 6.32%
2002 38.831.971 13.03%
2003 45.673.000 14.98%
2004 47.953.963 4.76%
2005 44.675.000 -7.34%
2006 61.531.991 27.4%
2007 61.868.793 0.54%
2008 70.648.000 12.43%
2009 72.499.000 2.55%
2010 95.616.000 24.18%
2011 100.676.000 5.03%
2012 100.046.000 -0.63%
2013 110.996.000 9.87%
2014 129.510.000 14.3%
2015 129.099.000 -0.32%
2016 120.624.000 -7.03%
2017 127.316.000 5.26%
2018 107.684.000 -18.23%
2019 110.685.000 2.71%
2020 133.423.000 17.04%
2021 157.540.000 15.31%
2022 130.461.000 -20.76%
2023 122.437.000 -6.55%
2023 120.136.000 -1.92%
2024 119.099.000 -0.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

National Research Corporation Liabilities
Year Liabilities Growth
1993 1.078.000
1994 1.916.000 43.74%
1995 3.166.000 39.48%
1996 4.100.000 22.78%
1997 4.500.000 8.89%
1998 8.900.000 49.44%
1999 10.700.000 16.82%
2000 10.255.042 -4.34%
2001 10.418.994 1.57%
2002 10.813.696 3.65%
2003 13.249.000 18.38%
2004 12.936.306 -2.42%
2005 12.082.000 -7.07%
2006 24.781.478 51.25%
2007 19.582.360 -26.55%
2008 32.050.000 38.9%
2009 28.328.000 -13.14%
2010 47.032.000 39.77%
2011 45.122.000 -4.23%
2012 43.304.000 -4.2%
2013 39.241.000 -10.35%
2014 41.762.000 6.04%
2015 54.877.000 23.9%
2016 37.818.000 -45.11%
2017 37.275.000 -1.46%
2018 88.601.000 57.93%
2019 77.793.000 -13.89%
2020 69.108.000 -12.57%
2021 72.203.000 4.29%
2022 58.428.000 -23.58%
2023 73.482.000 20.49%
2023 62.264.000 -18.02%
2024 78.901.000 21.09%

National Research Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.13
Net Income per Share
1.23
Price to Earning Ratio
15.9x
Price To Sales Ratio
3.18x
POCF Ratio
11.53
PFCF Ratio
20.49
Price to Book Ratio
11.57
EV to Sales
3.47
EV Over EBITDA
11.14
EV to Operating CashFlow
12.57
EV to FreeCashFlow
22.33
Earnings Yield
0.06
FreeCashFlow Yield
0.05
Market Cap
0,47 Bil.
Enterprise Value
0,51 Bil.
Graham Number
6.82
Graham NetNet
-2.96

Income Statement Metrics

Net Income per Share
1.23
Income Quality
1.38
ROE
0.64
Return On Assets
0.25
Return On Capital Employed
0.54
Net Income per EBT
0.77
EBT Per Ebit
0.97
Ebit per Revenue
0.27
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.59
Operating Profit Margin
0.27
Pretax Profit Margin
0.26
Net Profit Margin
0.2

Dividends

Dividend Yield
0.02
Dividend Yield %
2.46
Payout Ratio
1.24
Dividend Per Share
0.48

Operating Metrics

Operating Cashflow per Share
1.69
Free CashFlow per Share
0.95
Capex to Operating CashFlow
0.44
Capex to Revenue
0.12
Capex to Depreciation
2.97
Return on Invested Capital
0.37
Return on Tangible Assets
0.52
Days Sales Outstanding
25.87
Days Payables Outstanding
7.53
Days of Inventory on Hand
0
Receivables Turnover
14.11
Payables Turnover
48.5
Inventory Turnover
60093000
Capex per Share
0.74

Balance Sheet

Cash per Share
0,02
Book Value per Share
1,68
Tangible Book Value per Share
-0.96
Shareholders Equity per Share
1.68
Interest Debt per Share
1.78
Debt to Equity
1.05
Debt to Assets
0.35
Net Debt to EBITDA
0.92
Current Ratio
0.37
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,06 Bil.
Invested Capital
69784000
Working Capital
-0,03 Bil.
Intangibles to Total Assets
0.53
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
1
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

National Research Corporation Dividends
Year Dividends Growth
2014 0
2015 1 0%
2016 0 0%
2017 0 0%
2018 1 100%
2019 1 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 1 100%
2024 0 0%

National Research Corporation Profile

About National Research Corporation

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

CEO
Mr. Michael D. Hays
Employee
435
Address
1245 Q Street
Lincoln, 68508

National Research Corporation Executives & BODs

National Research Corporation Executives & BODs
# Name Age
1 Megan Charko
Senior Manager of Content Marketing
70
2 Ms. Linda Stacy
Secretary
70
3 Mr. Michael D. Hays
Founder, Chief Executive Officer, President & Director
70
4 Mr. Jason Hahn
Chief Revenue Officer
70
5 Ms. Vinitha Ramnathan
Chief Product Officer
70
6 Ms. Helen L. Hrdy
Chief Customer Officer
70
7 Mr. Andy Monnich
Chief Corporate Development Officer
70
8 Mr. Jon Boumstein
Chief Delivery Officer
70
9 Mr. Christophe Louvion
Chief Product & Technology Officer
70

National Research Corporation Competitors